{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-057906","form_type":"8-K","ticker":"ALNY","cik":"0001178670","company_name":"ALNYLAM PHARMACEUTICALS, INC.","filed_at":"2024-03-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.575976+00:00","generated_at":"2026-06-05T04:34:59.115842+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Alnylam announces departure of EVP, Chief Legal Officer Indrani Franchini","bullets":["Separation effective March 1, 2024; severance of $597,000 (12 months' base salary) paid bi-weekly.","Lump sum payment for 2023 annual incentive plan bonus, adjusted by corporate multiplier determined by Board.","One-year consulting arrangement through March 2025; continued vesting of unvested equity awards during consulting period.","$500/hour compensation for consulting beyond 10 hours per month; up to $15,000 legal fee reimbursement.","Consulting period; outstanding stock options remain exercisable for 3 months after consulting period; non-compete restrictions waived."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-057906","json":"https://secwatch.observer/filing/0001193125-24-057906.json","markdown":"https://secwatch.observer/filing/0001193125-24-057906.md","text":"https://secwatch.observer/filing/0001193125-24-057906.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1178670/000119312524057906/0001193125-24-057906-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1178670/000119312524057906/d746189d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T04:34:59.115842+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0895b3e32f","claim":"Indrani L. Franchini changed role as Executive Vice President, Chief Legal Officer and Secretary at ALNYLAM PHARMACEUTICALS, INC..","evidence_excerpt":"Indrani L. Franchini agreed that she would transition from her role as the Company’s Executive Vice President, Chief Legal Officer and Secretary, effective as of March 1, 2024","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1178670/000119312524057906/0001193125-24-057906-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"transitioned"},{"label":"Role","value":"Executive Vice President, Chief Legal Officer and Secretary"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}